Intranasal immunization with inactivated influenza vaccine. (Q30322979)

18 June 2017

title

Intranasal immunization with inactivated influenza vaccine. (English)

1 reference

18 June 2017

0 references

Potter CW

1 reference

18 June 2017

Jennings R

series ordinal

1 reference

18 June 2017

publication date

1 October 1999

1 reference

Pharmaceutical science & technology today

18 June 2017

published in

1 reference

18 June 2017

1 reference

18 June 2017

1 reference

18 June 2017

page(s)

402-408

1 reference

A Virus Obtained from Influenza Patients

18 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

RESULTS OF IMMUNIZATION BY MEANS OF ACTIVE VIRUS OF HUMAN INFLUENZA.

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Pathways of evolution of influenza A (H1N1) viruses from 1977 to 1986 as determined by oligonucleotide mapping and sequencing studies

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Determinants of immunity to influenza infection in man

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Effect of neuraminidase antibody on Hong Kong influenza

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Declining T-cell immunity to influenza, 1977-82

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Improvement of Inactivated Influenza Virus Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

The aging immune system: primer and prospectus

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

1 reference

7 January 2021

Interleukin-12 as adjuvant in peptide vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Pilot evaluation of influenza virus vaccine (IVV) combined with adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

A new surface-antigen-adsorbed influenza virus vaccine. II. Studies in a volunteer group

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Recombinant influenza-A viruses as live vaccines for man. Report to the Medical Research Council's Committee on Influenza and other Respiratory Virus Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Serological evaluation of an influenza A virus cold-adapted reassortant live vaccine, CR-37 (H1N1), in Japanese adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Characterization of the temperature sensitive phenotype of the A/Ann Arbor/6/60 cold-adapted virus and its recombinants

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Cytotoxic T lymphocyte memory: role in cross-protective immunity against influenza?

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Potential advantages of DNA immunization for influenza epidemic and pandemic planning

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Temperature-sensitive mutants of influenza virus. II. Attenuation of ts recombinants for man.

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

A comparison of subcutaneous, nasal, and combined influenza vaccination. I. Antigenicity

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

The efficacy of the A2/Aichi/68 strain in inhaled influenza immunisation against the A/England/42/72 variant.

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Immunity following intranasal administration of an inactivated, freeze-dried A/England/42/72 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Developments in mucosal influenza virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Enhancing effects of pertussis toxin B oligomer on the immunogenicity of influenza vaccine administered intranasally

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Immunopotentiation of local and systemic humoral immune responses by ISCOMs, liposomes and FCA: role in protection against influenza A in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Mechanism of enhancement of the immune responses to influenza vaccine with cholera toxin B subunit and a trace amount of holotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

IgA antibody-forming cell responses in the nasal-associated lymphoid tissue of mice vaccinated by intranasal, intravenous and/or subcutaneous administration

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS1461-5347%2899%2900194-7

7 January 2021

10.1016/S1461-5347(99)00194-7

Identifiers

DOI

1 reference

18 June 2017

1 reference